NEU 2.99% $20.10 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-143

  1. 100 Posts.
    lightbulb Created with Sketch. 125
    "In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable."
    Given that Neuren, post FDA approval, is now trading at a price around the same as after successful phase 2 results, why would a buyer pay a 300% premium?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.10
Change
-0.620(2.99%)
Mkt cap ! $2.569B
Open High Low Value Volume
$20.41 $20.45 $19.92 $5.947M 296.0K

Buyers (Bids)

No. Vol. Price($)
1 999 $20.10
 

Sellers (Offers)

Price($) Vol. No.
$20.19 10 1
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.